Nanoviricides (NNVC) Accumulated Expenses (2011 - 2026)
Nanoviricides (NNVC) posted Accumulated Expenses of $26000.0 for Q1 2026, down 46.26% sequentially from $48380.0 in Q4 2025, and down 20.28% YoY from $32616.0 in Q1 2025.
Nanoviricides (NNVC) Accumulated Expenses (2011 - 2026) Analysis & Trends
Nanoviricides has reported Accumulated Expenses for 16 years, with the latest figure at $26000.0 in Q1 2026.
- Quarterly Accumulated Expenses fell 20.28% year-over-year to $26000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $26000.0 (down 20.28% YoY) and the FY2025 annual result came in at $25969.0, up 10.36% from the prior year.
- Accumulated Expenses declined to $26000.0 in Q1 2026 per NNVC's latest filing, from $48380.0 in the prior quarter.
- Over five years, Accumulated Expenses peaked at $339623.0 in Q3 2023 and troughed at $23532.0 in Q2 2024.
- A 5-year average of $64646.5 and a median of $32616.0 in 2025 frame the typical range for Accumulated Expenses.
- The sharpest annual moves came in 2023 and 2025: Accumulated Expenses soared 1332.28% in 2023, then tumbled 87.4% in 2025.
- Over 5 years, Accumulated Expenses stood at $51877.0 in 2022, then slumped by 53.98% to $23872.0 in 2023, then grew by 10.18% to $26301.0 in 2024, then jumped by 83.95% to $48380.0 in 2025, then tumbled by 46.26% to $26000.0 in 2026.
- According to Business Quant data, Accumulated Expenses over the past three periods registered $26000.0, $48380.0, and $26300.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Nanoviricides | 28.74 Mn | 25.53 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 26,000.00 |
| Dec 31, 2025 | 48,380.00 |
| Sep 30, 2025 | 26,300.00 |
| Jun 30, 2025 | 25,969.00 |
| Mar 31, 2025 | 32,616.00 |
| Dec 31, 2024 | 26,301.00 |
| Sep 30, 2024 | 46,857.00 |
| Jun 30, 2024 | 23,532.00 |
| Mar 31, 2024 | 258,795.00 |
| Dec 31, 2023 | 23,872.00 |
| Sep 30, 2023 | 339,623.00 |
| Jun 30, 2023 | 39,060.00 |
| Mar 31, 2023 | 42,168.00 |
| Dec 31, 2022 | 51,877.00 |
| Sep 30, 2022 | 23,712.00 |
| Jun 30, 2022 | 38,676.00 |
| Mar 31, 2022 | 25,252.00 |
| Dec 31, 2021 | 24,157.00 |
| Sep 30, 2021 | 24,075.00 |
| Jun 30, 2021 | 24,285.00 |